Elite Pharmaceuticals (OTCMKTS:ELTP) Share Price Passes Below Two Hundred Day Moving Average – What’s Next?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTPGet Free Report)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.59 and traded as low as $0.4681. Elite Pharmaceuticals shares last traded at $0.50, with a volume of 254,398 shares traded.

Elite Pharmaceuticals Stock Performance

The company’s 50 day simple moving average is $0.55 and its 200 day simple moving average is $0.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.34 and a current ratio of 8.04. The stock has a market cap of $537.25 million, a PE ratio of 50.05 and a beta of 0.29.

Elite Pharmaceuticals Company Profile

(Get Free Report)

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

Featured Articles

Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.